The price of a course remdesivir, the first drug to show modest improvements in severely ill COVID-19 patients, could be set between $10 and $4,500, according to the Institute for Clinical and Economic Review. That wide range lays the parameters for the debate over how pandemic drugs should be priced. “The results of a cost recovery approach and a cost-effectiveness approach are going to produce very different pricing estimates,” ICER President Steven Pearson said. “Some may wish to view them...